Search

This research analyzes the type of microbial starter and fermentation time on the characteristics of Modified Tannia Flour (MOTIF) with randomized design— nine treatments and three replications. The treatments were F (Lactobacillus bulgaricus bacteria, lactic acid bacteria and Bimo-CF Starter) and P (fermentation time 24 h, 36 h and 48 h). Observed variables being resistant starch, swilling power and water-soluble index and color test (l, a, b). The research results showed that the best treatment was the starter type Lactobaccilus bulgaricus with 36 h of fermentation producing a content of 10.50 %, ash content of 1.64 %, resistant starch content of 24.21 % and swelling power of 35.38 %. The use of a starter type of lactic acid bacteria with a fermentation time of 36 h has characteristics of flour with a water content of 13.41 %, ash content of 1.70 %, resistant starch content of 23.93 % and swelling power of 34.99 %, while using Bimo-CF starter with a fermentation time of 36 h has characteristics of flour with a water content of 17.22 %, ash content of 1.51 %, resistant starch content of 24.36 % and swelling power of 35.44 %.

Extracted stevia leaves can be natural sweetener in pudding. This research aimed to obtain formulation of functional pudding with stevia leaf extract as a substitute for granulated sugar. This research used a simple randomized block design consisting of three replications. The treatments added were the proportion of sugar and stevia leaf extract, which consisted of six treatments, namely 170 g and 0 g, 136 g and 0.17 g, 102 g and 0.34 g, 68 g and 0.51 g, 34 g and 0.68 g, 0 g and 0.85 g. Variables of the tests carried out are rate fiber food, syneresis test, texture test, color test, pH test, and organoleptic test. The best treatment was pudding sugar 0 g and extract stevia leaves 0.85 g with average rate fiber 0.21 %, syneresis test 2.7167 mg min-1, gel strength 50.1 N, intensity color: brightness (L) 31.26, redness (a) 0.33, yellowish (b) 1.13, organoleptic: color 3.50 (fair), aroma 2.5 (no smell), taste 3.47 (enough delicious), texture 3.47 (enough soft), pH 7.41. Differences in the proportion of stevia leaf extract did not have a significant effect on the redness level and organoleptic variables of the pudding aroma but has a real effect on other variables, i.e rate fiber, syneresis, gel strength, brightness level, yellowish level, pH, color, taste, and texture.

This research aims to know the influence of suspension compared to its crude extract on antibacterial activity, especially for Escherichia coli and Staphylococcus aureus. An independent t-test was used as statistical analysis. The yield of the thick extract obtained was 11.153 % ± 1.032 % and it gave an inhibition zone of 7.878 mm ± 0.301 mm for Escherichia coli and 7.484 mm ± 0.636 mm for Staphylococcus aureus. While the suspensions gave an inhibitory zone of 6.293 mm ± 0.754 mm and 5.140 mm ± 0.121 mm for Escherichia coli and Staphylococcus aureus in sequence. The extract’s particle size followed by suspension was 951.167 mm ± 113.662 nm and 474.000 mm ± 38.500 nm. The independent t-test results showed that the extract and suspension significantly influenced the growth of Staphylococcus aureus and Escherichia coli with sig values of 0.012 and 0.028. In conclusion, the extract had a greater effect than the suspension on the growth of Staphylococcus aureus and Escherichia coli.

Le « Group for Research and Assessment of Psoriasis and Psoriatic Arthritis » (GRAPPA) et l'« European Alliance of Associations for Rheumatology » (EULAR) ont élaboré des recommandations pour le traitement du rhumatisme psoriasique (PsA) basées sur les données actuelles. Tous les médicaments antirhumatismaux biologiques modificateurs de la maladie (bDMARDs) sont recommandés à niveau égal pour l'arthrite périphérique. Les inhibiteurs (i) de l'interleukine 17 (IL-17) et de l'IL-12/23 sont à préférer aux inhibiteurs du facteur de nécrose tumorale (TNFi) en cas de large atteinte cutanée. Les IL-12/23i ne sont pas recommandés en cas de manifestations axiales. PRO-SPIRIT est la première étude observationnelle prospective internationale à large effectif dans le PsA. Les résultats de l'étude révèlent que les modalités de traitement en vie réelle reflètent les recommandations décrites dans le PsA. PRO-SPIRIT a inclus des adultes atteints de PsA entre 2019 et 2022, ayant initié ou été switché vers un médicament antirhumatismal biologique ou synthétique ciblé (b/tsDMARD). Les groupes de traitement comprenaient les inhibiteurs du TNF (TNFi), de l'IL-17A (IL-17Ai), de l'IL-12/23 (IL-12/23i), de l'IL-23 (IL-23i), les inhibiteurs de Janus kinase (JAKi), et de la phosphodiestérase-4 (PDE4i). Le mode d'action (MoA) était à la discrétion du médecin traitant. Les caractéristiques démographiques des patients, l'activité de la maladie, les caractéristiques du traitement et les résultats cliniques et rapportés par les patients ont été recueillis à l'inclusion. Des résultats descriptifs sont présentés. Les valeurs manquantes à l'inclusion ont été imputées. L'analyse inclut 1 192 patients atteints de PsA traités par différents MoA. Les patients présentant une arthrite (définie par un nombre d'articulations gonflées (NAG) et douloureuses (NAD) ≥ 5) étaient également répartis entre les classes thérapeutiques, sauf dans le groupe PDE4i (pourcentage plus faible). Les patients recevant des IL-17Ai présentaient fréquemment une atteinte articulaire, cutanée et unguéale. Les patients avec une atteinte cutanée plus importante (surface corporelle (BSA) ≥ 3 %) et unguéale étaient plus fréquemment traités par IL-17Ai et IL-23i, moins par JAKi. Les patients recevant des JAKi présentaient plus d'atteintes articulaires et axiales, et moins d'atteintes cutanées. Après les IL-23i, les PDE4i avaient la deuxième proportion la plus élevée de patients avec une atteinte unguéale. Les patients traités par PDE4i étaient peu nombreux et rapportaient généralement moins d'atteintes actives. Les résultats par ligne de traitement ont montré qu'une proportion plus importante de patients était traitée par IL-12/23i, JAKi et IL-17Ai après un traitement antérieur par b/tsDMARDs. En général, les patients présentaient une maladie polyarticulaire à l'inclusion. Les patients avec une atteinte cutanée et unguéale étaient plus fréquemment traités par IL-17Ai et IL-23i que par TNFi et JAKi. Les patients présentant des manifestations axiales étaient plus fréquemment traités par IL-17Ai et JAKi que par IL-12/23i et IL-23i. Ces résultats contribuent à alimenter les données sur les schémas thérapeutiques dans le PsA en vie réelle ainsi qu'aux recommandations pour guider un traitement individualisé du PsA. [ABSTRACT FROM AUTHOR]

The performance enhancement of asphalt binders by incorporating polyethylene has been a subject of significant research for scientists working on flexible pavements and environmental sustainability. Various types of polyethylene (PE), including low-density polyethylene (LDPE) and high-density polyethylene (HDPE), are utilized in asphalt binders. To fully leverage the benefits of PE, it is crucial to verify its characteristics. This study investigates asphalt performance using LDPE and HDPE modifiers. The impact of different types of polyethylene on the performance of asphalt was examined through conventional properties and rheological properties such as Penetration, softening point, ductility, rotational viscosity, failing temperature as well as Superpave rutting parameter (G*/sinδ). Storage stability criteria and microscopic characterization were employed to access compatibility. The findings revealed that both the LDPE and HDPE have a good impact on high-temperature characteristics of asphalt binder; however, among the tested samples, HDPE-modified asphalt exhibited the highest G*/sinδ, and viscosity, making it a superior choice for improving rutting resistance. The LDPE shows greater storage stability compared to HDPE, making it particularly suitable for application in asphalt binders.

The synthesis Poly[1,5-naphthyridine-(3-hexylthiophene)] (PN3HTh) semi-conducting polymer has been accomplished by adopting both conventional and microwave-assisted Suzuki-Miyaura cross-coupling reaction between 3-hexylthiophene-2,5-diboronic ester and 2,6-dibromo-1,5-naphthyridine. The electrochemical and transport properties of PN3HTh were investigated both in the bulk as well as in thin film form. These properties can be further tuned by changing the solvent and the nature of the electrode used. Consequently, cyclic voltammetry (CV) measurements were conducted using a potentiostat coupled with an electrochemical cell. The CV results of PN3HTh as a bulk form in H2SO4 solution indicated that the concentration of the polymer in the solution is not well defined because of polymer poor solubility in aqueous solutions. On the other hand, the sulfur group which works as electron donating makes the system more electron-rich. This can explain by the absence of the reduction peak. For the thin film, two single oxidation peaks were obtained at around 0 V and 0.3 V for both cases. Different solvents can tune the transport properties of the polymer as can be seen from the two CVs where BF3 exhibited enhanced transport properties over ACN. The synthesized polymers were characterized by modern spectroscopic methods including IR and NMR.